CN105434386A - Sustained release tablet containing high water-soluble active ingredients and preparation method thereof - Google Patents
Sustained release tablet containing high water-soluble active ingredients and preparation method thereof Download PDFInfo
- Publication number
- CN105434386A CN105434386A CN201510893423.5A CN201510893423A CN105434386A CN 105434386 A CN105434386 A CN 105434386A CN 201510893423 A CN201510893423 A CN 201510893423A CN 105434386 A CN105434386 A CN 105434386A
- Authority
- CN
- China
- Prior art keywords
- slow
- release material
- water
- soluble active
- active component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the technical field of pharmaceutical preparations and particularly relates to a sustained release tablet containing high water-soluble active ingredients and a preparation method thereof. The sustained release tablet comprises, by weight percentage, 45%-70% of high water-soluble active ingredients, 0.3%-4% of first sustained-release material, 27%-51% of second sustained-release material, 0-18% of diluent and 0.1%-1.0% of lubricant. The first sustained-release material and the second sustained-release material can be the same or different and are selected from one or more of hydroxypropyl methylcellulose, hydroxy propyl cellulose, sodium carboxymethyl cellulose, carmellose calcium, povidone, carbomer and polyoxyethylene. Compared with the existing sustained release tablet, the sustained release tablet containing the high water-soluble active ingredients is good in compressibility, low in cost and good in quality, and the hardness cannot be reduced after long-term storage.
Description
Technical field
The present invention relates to pharmaceutical preparations technology field, be specifically related to a kind of slow releasing tablet containing highly-water-soluble active component and preparation method thereof.
Background technology
For highly-water-soluble active component, ordinary tablet has following shortcoming: (1) highly-water-soluble active component is soluble in water, the rapid stripping of drug after oral administration, and high amount of drug is through gastrointestinal tract, only be partially absorbed at small intestine site, cause bioavailability low; (2) in gastrointestinal tract, highly-water-soluble activity component concentration is too high, to untoward reaction such as the obvious stimulation of gastrointestinal tract mucous generation and generation lactic acidosis; (3) ordinary tablet needs every day often oral, and compliance is poor, and forgetting takes medicine can affect the effect of medicine.Therefore, for highly-water-soluble active component, be necessary to develop a kind of slow releasing preparation.Slow releasing preparation can ensure that medicine steadily discharges and extends the afterbody holdup time, makes patient more comfortable; Owing to adopting slow release method, medicine dissolves at gastric and greatly reduces, and avoids the stimulation to stomach.
Because some highly-water-soluble active component are crystalline powder, poor fluidity, the non-constant of compressibility, all can not tabletted under any pressure.Reduced further by its compressibility after granulating, make the tablet hardness range of preparation very narrow, be unfavorable for the quality control of the large production of commercialization; Simultaneously also because the high unit dose that highly-water-soluble active component is usually required is more than or equal to 500mg/ sheet, available adjuvant quantity space is limited.Therefore, slow releasing tablet adopts following preparation method usually:
1, tabletting after adopting dry granulating machine to granulate.But the non-constant of the compressibility due to highly-water-soluble active component, is reduced further by its compressibility after dry granulation, makes the tablet hardness range of preparation very narrow, produce and be difficult to control.In addition, dry granulation process is complicated, and influence factor is various, and compactibility and the particle size distribution of particularly prepared granule can produce significant impact to product quality, are unfavorable for the quality control of the large production of commercialization.
2, direct compression technique is adopted.Because the viscosity of slow-release material is very large, when mixing with highly-water-soluble active component, may occur mixing problem of non-uniform; The particle diameter of slow-release material is little, poor fluidity, and recipe quantity is large, and particle diameter difference all affects the quality of prescription mobility, and then causes tablet weight variation unstable.
3, with an organic solvent.In pelletization, employ organic solvent, in production process, not only will adopt explosion precaution, also will the organic solvent in product be removed, greatly add insecurity in production process and production cost improves greatly.
4, common tabletting bag Co ntrolled release clothing film to be reached slow release effect.This invention employs organic solvent in coating process, not only will adopt explosion precaution in production process, also will remove the organic solvent in product, greatly adds insecurity in production process and production cost improves greatly.In addition, manufacturing process is loaded down with trivial details.
5, add diluent before tabletting, reduce the consumption of controlled-release material, reach the object of Drug controlled release speed.40% is greater than for active component content, and the tablet of compressibility extreme difference, after wet granulation, the compressibility of material reduces greatly, produces the problem that hardness range is narrow.Even if add the diluent less than 5%, can not solve at all.
6, the controlled-release material of different stage is used to control the rate of release of medicine.Rate of release difference between the tablet batch that this preparation method obtains is large, will affect its effectiveness and safety like this.
Therefore, people are good for compliance, and drug release is steady, and compressibility is good, and the higher slow releasing preparation of the quality that after long term storage, hardness can not decline still exists demand.
Summary of the invention
For above-mentioned the deficiencies in the prior art, the invention provides a kind of slow releasing tablet containing highly-water-soluble active component newly.
The present invention also provides the preparation method of the above-mentioned slow releasing tablet containing highly-water-soluble active component.
Object of the present invention is achieved through the following technical solutions:
A slow releasing tablet containing highly-water-soluble active component, wherein, component and the weight percent content thereof of described slow releasing tablet are as follows:
Described first slow-release material and the second slow-release material can be identical or different, and are selected from one or more in hypromellose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, carboxymethylcellulose calcium, polyvidone, carbomer, polyoxyethylene.
Described first slow-release material and the second slow-release material, after specific Adding Way prepares granule, substantially improve the dry jet mixing pile of mixed material, comprise compressibility and mobility.
Relative to existing slow releasing tablet, slow releasing tablet compressibility of the present invention is good, and in addition, cost is lower, quality good, and after long term storage, hardness can not decline.
Preferably, described slow releasing tablet first by comprising highly-water-soluble active component and the mixing of the first slow-release material is added water and make granule, then be prepared from the wet granule compression tablet method that the second slow-release material and diluent carry out the step of granulating.
For the highly-water-soluble active component of the non-constant of compressibility, the present inventor is surprised to find that in an experiment, fashionable when slow-release material being added step by step in pelletization, the wet granular size obtained is even, a large amount of large crumbs and fine powder can not be there is because of a large amount of high viscosity controlled-release material of use, fast drying, can accurately determine dry terminal.Can greatly improve slow releasing tablet compressibility and long-term place after hardness can not change, prepared slow releasing tablet effectively can control the release of medicine.And it is defective to overcome the tablet weight variation caused by plus slow release material in prior art thus, the defects such as preparation process is loaded down with trivial details, achieve unforeseeable beneficial effect.
Preferably, the weight ratio of described first slow-release material and the second slow-release material is 1:10 ~ 90.The content of the first slow-release material and the second slow-release material, can synergism thus ensure the release that the hardness that tablet has good formability and necessity in tableting processes is become reconciled in above-mentioned proportion.
Preferably, described second slow-release material is hypromellose, or is the mixture of hypromellose cellulose content more than 30% weight.
Described hypromellose (such as hypromellose K100MCR) belongs to the gel-type skeleton slow-release material of imbibition, as main slow-release material, independent or used in combination with other slow-release materials, make active component discharge steadily better effects if slowly.
Further preferably, described second slow-release material is full-bodied hypromellose (viscosity is 75000 ~ 140000Pas), is particularly preferably hydroxypropyl cellulose K100MCR.For the present invention, the hydroxypropyl cellulose of K100MCR rank has the particle diameter and viscosity that are more suitable for preparing slow releasing tablet, make tablet have good hardness and stable drug release, avoid tablet rupture in transportation, prominent the releasing at initial stage discharge incomplete problem with the later stage.
Preferably, described diluent is selected from one or more in pregelatinized Starch, microcrystalline Cellulose, dextrin, calcium hydrogen phosphate; Described lubricant is one or more in magnesium stearate, calcium stearate, zinc stearate, aluminium stearate, stearic acid, magnesium carbonate, magnesium oxide, Pulvis Talci, silicon dioxide, micropowder silica gel, Polyethylene Glycol, hydrogenated vegetable oil, sodium laurylsulfate.Described diluent has good mobility and compressibility, can improve the hardness of tablet further.
More preferably, described diluent is microcrystalline Cellulose; More preferably its mean diameter is 50 μm, and it has and obtains the surface area that adapts of slow releasing tablet property of the present invention and cavernous structure, and corresponding tabletting performance, can ensure the hardness of tablet and cheap.Described lubricant is magnesium stearate, and it is a kind of excipient substance of extensive use, is cheaply easy to get, and does not affect product quality, as hardness; In addition, make tablet surface smooth.
Preferably, the component of described slow releasing tablet and weight percent content as follows:
Wherein, the weight ratio of described first slow-release material and the second slow-release material is 1:10 ~ 50.
When this formula, the performance of obtained slow releasing tablet is improved further.
Most preferably, the component of described slow releasing tablet and weight percent content as follows:
Wherein, the weight ratio of described first slow-release material and the second slow-release material is 1:15 ~ 30.
When this formula, the performance of obtained slow releasing tablet is further improved.
Described " highly-water-soluble active component " is defined as the material with therapeutic effect.
Described " highly-water-soluble active component " refers to that active component is very easily water-soluble, and in water, dissolubility is greater than the material of 100mg/mL.
According to one embodiment of the invention, described highly-water-soluble active component is selected from two valproic acid or its salt, nicotinic acid, metformin or its pharmaceutically acceptable derivates.
A preparation method for slow releasing tablet containing highly-water-soluble active component, it comprises the following steps:
(1) by highly-water-soluble active component and the mixing of the first slow-release material, add water and make granule; Then add the second slow-release material and diluent to carry out granulation and obtain wet granular;
(2) above-mentioned wet grain drying is obtained dry granule, then granulate is carried out to dry granule;
(3) granule after above-mentioned granulate and lubricant are mixed obtain material, then tabletting and get final product.
Preferably, in step (2), the aperture of the screen cloth of described granulate is 0.6 ~ 2.5mm, more preferably 1.0 ~ 2.0mm, further preferred 1.5mm.This step can use such as pelletizing machine to carry out.
Preferably, described lubricant is what sieve in advance, and sieve number is 16 ~ 30 orders, is more preferably 16 ~ 25 orders, more preferably 20 orders.
Of the present invention containing in the slow releasing tablet of highly-water-soluble active component, the content of highly-water-soluble active component is very high, and therefore highly-water-soluble active component content one timing, its size is less, and patient swallows easily, and administration compliance is good.
The content specification of the slow releasing tablet containing highly-water-soluble active component of the present invention can be arranged according to the needs of administering mode usually flexibly.The absolute content of highly-water-soluble active component is generally 500mg/ sheet ~ 1000mg/ sheet.
Except as otherwise noted, percentage ratio " % " of the present invention is the percentage by weight based on unitary tablet.Further, in unit formulation, each component percentages content sum is 100%.
The prescription compressibility of slow releasing tablet of the present invention is good, ensures that active component rate of release is steady, makes tablet quality more guaranteed.
Preparation method technique of the present invention is comparatively simple, and cost is lower, and the slow releasing tablet prepared and existing medicine have suitable therapeutic effect.
The various adjuvants that slow releasing tablet of the present invention uses, commercially can very easily buy, and low price, so tablet cost of the present invention is low, the medication burden of patient significantly can be alleviated.In addition, preparation technology of the present invention is simple, and controllability is strong, easily operates.
Accompanying drawing explanation
Fig. 1 is the slow releasing tablet prepared of embodiment 1 and formerly grinds the stripping curve of medicine in pH6.8 phosphate-buffered liquid medium.
Detailed description of the invention
The invention discloses good slow releasing tablet containing highly-water-soluble active component of a kind of compressibility and preparation method thereof.Based on the description of above summary of the invention, those skilled in the art can apply the present invention all sidedly, and all same principle or similar change all should be considered as comprising within the scope of the present invention.
In order to better understand and illustrate the present invention, just slow releasing tablet containing highly-water-soluble active component provided by the invention and preparation method thereof provides exemplary illustration below, but it should not be understood to the restriction to summary of the invention.
In following examples, device therefor instrument mainly comprises:
G20 type wet mixing pelletizer; BSL-25 type mixer; FZB type crushing and pelletizing machine; ZP10A type tablet machine; YD-35 tablet hardness instrument; RC806 digestion instrument.
Embodiment 1
Prescription is as shown in table 1:
Table 1:1000 sheet diabecron sustained-release tablet (750mg/ sheet) prescription
According to recipe quantity in upper table, highly-water-soluble active ingredient hydrochloric acid metformin and the first slow-release material sodium carboxymethyl cellulose are placed in wet mixing pelletizer; arranging mixing speed is 200 ~ 250 revs/min; cutter speed is 2000 ~ 3000 revs/min; add the granule that appropriate purified water makes suitable size after being dry mixed gradually, then add the second slow-release material hypromellose K100MCR and granulate in granulation pot.Obtained wet granular moves in fluid bed dry, and temperature of charge is 50 DEG C, and the screen cloth of 1.5mm obtains the granule containing metformin hydrochloride excessively afterwards.The lubricant of recipe quantity is crossed after 20 mesh sieves and above-mentioned metformin hydrochloride granule mix homogeneously, the tablet of adjustment compression force compacting different hardness.
Embodiment 2
Prescription is as shown in table 2:
Table 2:1000 sheet niacin slow-release tablet (750mg/ sheet) prescription
The preparation method identical with embodiment 1 is adopted to prepare slow releasing tablet.
Embodiment 3
Prescription is as shown in table 3:
Table 3:1000 sheet Divalproex sodium sustained-release tablet (500mg/ sheet) prescription
Except being added together with diluent by the second slow-release material, the preparation method identical with embodiment 1 is adopted to prepare slow releasing tablet.
Embodiment 4
Prescription is as shown in table 4:
Table 4:1000 sheet niacin slow-release tablet (750mg/ sheet) prescription
The preparation method identical with embodiment 1 is adopted to prepare slow releasing tablet.
Embodiment 5
Prescription is as shown in table 5:
Table 5:1000 sheet Divalproex sodium sustained-release tablet (500mg/ sheet) prescription
Except being added together by two kind of second slow-release material, the preparation method identical with embodiment 1 is adopted to prepare slow releasing tablet.
Comparative example 1
Prescription is identical with table 1 in embodiment 1.Its preparation method is:
According to recipe quantity in table 1, highly-water-soluble active ingredient hydrochloric acid metformin, the first slow-release material sodium carboxymethyl cellulose and the second slow-release material hypromellose K100MCR are placed in wet mixing pelletizer; arranging mixing speed is 200 ~ 250 revs/min; cutter speed is 2000 ~ 3000 revs/min; add appropriate purified water after being dry mixed gradually and make granule; obtained wet granular moves in fluid bed dry; temperature of charge is 50 DEG C, and the screen cloth of 1.5mm obtains the granule containing metformin hydrochloride excessively afterwards.The lubricant of recipe quantity is crossed after 20 mesh sieves and above-mentioned metformin hydrochloride granule mix homogeneously, the tablet of adjustment compression force compacting different hardness.
Experimental example 1 embodiment 1 grinds medicine slow releasing tablet dissolution determination with former
In American Pharmacopeia 37 editions, the dissolving-out method of diabecron sustained-release tablet adopts dissolution method (the second method, paddle method):
Digestion instrument: Tian Fa Science and Technology Ltd. of University Of Tianjin RC806;
Dissolution medium: pH6.8 phosphate buffer, 1000ml;
Chromatographic column: Agilent, ZorbaxSBC18,4.6mmx150mm, 5 μm;
Dissolution medium temperature: 37 DEG C;
Former manufacturer of grinding medicine is: Bristol Myers Squibb.
Method 2 (paddle method): 100rpm; Time: 1 hour, 2 hours and 10 hours.
The contrast of result and conclusion:
Fig. 1 is the diabecron sustained-release tablet agent prepared of embodiment 1 and formerly grinds the Dissolution profiles figure of medicine in pH6.8 phosphate-buffered liquid medium.Its middle polyline A is the former Dissolution profiles grinding medicine, and broken line B is the Dissolution profiles of slow releasing tablet prepared by embodiment 1.
As shown in Figure 1, the Dissolution profiles of diabecron sustained-release tablet prepared by the present invention is identical with former Dissolution profiles trend of grinding medicine, and similar factors is 74.Illustrate that the present invention contains the dissolution of the slow releasing tablet of metformin hydrochloride and former to grind medicine closely similar, therefore both can reach closely similar therapeutic effect.But the slow releasing tablet preparation method that the present invention contains metformin hydrochloride is simple, and easily realize, cost obviously reduces.
Dissolution determination is carried out to slow releasing tablet prepared by embodiment 2 ~ 5, its dissolution and former to grind medicine also closely similar.
The mensuration of experimental example 2 embodiment 1, embodiment 3, embodiment 5 and comparative example 1 slow releasing tablet compressibility
Each 10 of the product of Example 1,3 and comparative example 1, is placed in hardness tester, carries out hardness measurement.
After 12 months, hardness test is carried out under the tablet placement room temperature condition of Example 5.
According to Chinese Pharmacopoeia 2010 editions annex VE tablet friability inspection techniques: get 10, blow away the powder come off with hair-dryer, precise weighing, put in cylinder, rotate 100 times.Take out, with method removing powder, precise weighing.Counting loss weight, obtains friability numerical value.Result is as follows.
Table 6: embodiment 1 slow releasing tablet hardness range
Table 7: embodiment 3 slow releasing tablet hardness range
Table 8: comparative example 1 slow releasing tablet hardness range
Table 9: the embodiment 5 slow releasing tablet room temperature hardness test result of 12 months
The contrast of result and conclusion:
From table 6 and table 7, in the preparation method of slow releasing tablet of the present invention, after the first slow-release material and the second slow-release material gradation add granulation, the total mixed powder obtained has very wide hardness range, illustrates that it has good compressibility.Therefore, when the first slow-release material and the second slow-release material gradation add granulation, compressibility and the release of tablet are fine.
As seen from Table 8, after slow-release material adds granulation simultaneously, the total mixed powder adjustment compression force obtained all can not obtain the qualified hardness range of friability, illustrates that its preparation technology is not suitable for.
As seen from Table 9, after the slow releasing tablet that preparation method of the present invention obtains is placed for a long time, its hardness can not change, and illustrates that its preparation technology is suitable.
Claims (10)
1. the slow releasing tablet containing highly-water-soluble active component, it is characterized in that, component and the weight percent content thereof of described slow releasing tablet are as follows:
Described first slow-release material and the second slow-release material identical or different, and one or more being selected from hypromellose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, carboxymethylcellulose calcium, polyvidone, carbomer, polyoxyethylene.
2. the slow releasing tablet containing highly-water-soluble active component according to claim 1, it is characterized in that, described slow releasing tablet first by comprising highly-water-soluble active component and the mixing of the first slow-release material is added water and make granule, then be prepared from the wet granule compression tablet method that the second slow-release material and diluent carry out the step of granulating.
3. the slow releasing tablet containing highly-water-soluble active component according to claim 1, it is characterized in that, the weight ratio of described first slow-release material and the second slow-release material is 1:10 ~ 90.
4. the slow releasing tablet containing highly-water-soluble active component according to claim 1, it is characterized in that, described second slow-release material is hypromellose, or is the mixture of hypromellose cellulose content more than 30% weight.
5. the slow releasing tablet containing highly-water-soluble active component according to claim 1, is characterized in that, described diluent be selected from pregelatinized Starch, microcrystalline Cellulose, dextrin, calcium hydrogen phosphate one or more; Described lubricant be selected from magnesium stearate, calcium stearate, zinc stearate, aluminium stearate, stearic acid, magnesium carbonate, magnesium oxide, Pulvis Talci, silicon dioxide, micropowder silica gel, Polyethylene Glycol, hydrogenated vegetable oil, sodium laurylsulfate one or more; Described highly-water-soluble active component is selected from two valproic acid or its salt, nicotinic acid, metformin or its pharmaceutically acceptable derivates.
6. the slow releasing tablet containing highly-water-soluble active component according to claim 1, it is characterized in that, described second slow-release material is full-bodied hypromellose, is preferably hydroxypropyl cellulose K100MCR; Described diluent is microcrystalline Cellulose, and described lubricant is magnesium stearate.
7. the slow releasing tablet containing highly-water-soluble active component according to claim 1, it is characterized in that, component and the weight percent content thereof of described slow releasing tablet are as follows:
Wherein, the weight ratio of described first slow-release material and the second slow-release material is 1:10 ~ 50.
8. the slow releasing tablet containing highly-water-soluble active component according to claim 1, it is characterized in that, component and the weight percent content thereof of described slow releasing tablet are as follows:
Wherein, the weight ratio of described first slow-release material and the second slow-release material is 1:15 ~ 30.
9. a preparation method for the slow releasing tablet containing highly-water-soluble active component according to any one of claim 1 ~ 8, is characterized in that, comprise the following steps:
(1) by highly-water-soluble active component and the mixing of the first slow-release material, add water and make granule; Then add the second slow-release material and diluent to carry out granulation and obtain wet granular;
(2) above-mentioned wet grain drying is obtained dry granule, then granulate is carried out to dry granule;
(3) granule after above-mentioned granulate and lubricant are mixed obtain material, then tabletting and get final product.
10. the preparation method of the slow releasing tablet containing highly-water-soluble active component according to claim 9, it is characterized in that, in step (2), the aperture of the screen cloth of described granulate is 0.6 ~ 2.5mm, more preferably 1.0 ~ 2.0mm, most preferably 1.5mm; Described lubricant is what sieve in advance, and sieve number is 16 ~ 30 orders, is more preferably 16 ~ 25 orders, most preferably is 20 orders.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510893423.5A CN105434386B (en) | 2015-12-08 | 2015-12-08 | A kind of sustained-release tablet containing highly-water-soluble active constituent and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510893423.5A CN105434386B (en) | 2015-12-08 | 2015-12-08 | A kind of sustained-release tablet containing highly-water-soluble active constituent and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105434386A true CN105434386A (en) | 2016-03-30 |
| CN105434386B CN105434386B (en) | 2018-06-22 |
Family
ID=55545324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510893423.5A Active CN105434386B (en) | 2015-12-08 | 2015-12-08 | A kind of sustained-release tablet containing highly-water-soluble active constituent and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105434386B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018177318A1 (en) * | 2017-04-01 | 2018-10-04 | 重庆康刻尔制药有限公司 | Metformin hydrochloride sustained-release tablets and preparation method therefor |
| WO2018177317A1 (en) * | 2017-04-01 | 2018-10-04 | 重庆康刻尔制药有限公司 | Method for preparing metformin hydrochloride sustained-release tablets |
| CN111588701A (en) * | 2020-05-25 | 2020-08-28 | 上海普康药业有限公司 | Metformin hydrochloride sustained release tablet and preparation method thereof |
| CN112168796A (en) * | 2020-09-28 | 2021-01-05 | 北京诺康达医药科技股份有限公司 | Controlled-release drug sustained-release preparation of biphasic sustained-release system and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850033A (en) * | 2006-03-07 | 2006-10-25 | 中国药科大学 | Water soluble anti-cancer medicine slow-release fiber preparation and preparing method therefor |
| CN101288652A (en) * | 2007-09-30 | 2008-10-22 | 西北工业大学 | Water-soluble drug sustained-release tablet and preparation method thereof |
| CN101444486A (en) * | 2008-06-20 | 2009-06-03 | 广东药学院 | Water-soluble drug sustained-release microsphere and preparation method and applications thereof |
| CN101518518A (en) * | 2008-12-12 | 2009-09-02 | 山东京卫制药有限公司 | Niacin simvastatin sustained-release preparation and preparation method thereof |
-
2015
- 2015-12-08 CN CN201510893423.5A patent/CN105434386B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1850033A (en) * | 2006-03-07 | 2006-10-25 | 中国药科大学 | Water soluble anti-cancer medicine slow-release fiber preparation and preparing method therefor |
| CN101288652A (en) * | 2007-09-30 | 2008-10-22 | 西北工业大学 | Water-soluble drug sustained-release tablet and preparation method thereof |
| CN101444486A (en) * | 2008-06-20 | 2009-06-03 | 广东药学院 | Water-soluble drug sustained-release microsphere and preparation method and applications thereof |
| CN101518518A (en) * | 2008-12-12 | 2009-09-02 | 山东京卫制药有限公司 | Niacin simvastatin sustained-release preparation and preparation method thereof |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018177318A1 (en) * | 2017-04-01 | 2018-10-04 | 重庆康刻尔制药有限公司 | Metformin hydrochloride sustained-release tablets and preparation method therefor |
| WO2018177317A1 (en) * | 2017-04-01 | 2018-10-04 | 重庆康刻尔制药有限公司 | Method for preparing metformin hydrochloride sustained-release tablets |
| CN111588701A (en) * | 2020-05-25 | 2020-08-28 | 上海普康药业有限公司 | Metformin hydrochloride sustained release tablet and preparation method thereof |
| CN111588701B (en) * | 2020-05-25 | 2021-04-23 | 上海普康药业有限公司 | Metformin hydrochloride sustained release tablet and preparation method thereof |
| CN112168796A (en) * | 2020-09-28 | 2021-01-05 | 北京诺康达医药科技股份有限公司 | Controlled-release drug sustained-release preparation of biphasic sustained-release system and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105434386B (en) | 2018-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020249001A1 (en) | Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor | |
| KR101977785B1 (en) | Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof | |
| CN105434386A (en) | Sustained release tablet containing high water-soluble active ingredients and preparation method thereof | |
| CN103479592B (en) | Metformin hydrochloride sustained release tablets and preparation method thereof | |
| JP5367735B2 (en) | Tablet manufacturing method | |
| CN109875972B (en) | Olmesartan medoxomil and amlodipine pharmaceutical composition | |
| CN112603900A (en) | Solid preparation containing [ (4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl) -amino ] -acetic acid | |
| CN104434845B (en) | A kind of solid pharmaceutical preparation for including the western croak of Leo | |
| CN114302712B (en) | Acipimox multi-unit sustained-release pellet tablet and preparation method thereof | |
| CN102988297A (en) | Roflumilast solid dispersion and medicinal composition containing same | |
| CN106456640B (en) | Ceritinib preparation | |
| CN103083326A (en) | Ulipristal acetate medicine composition | |
| CN102764254A (en) | Levetiracetam drug composition and preparation method thereof | |
| CN111888477B (en) | Bedaquinoline pharmaceutical preparation | |
| CN105055350A (en) | Preparation method of proton pump inhibitor-containing tablet | |
| CN111467317B (en) | Pharmaceutical composition containing atorvastatin calcium and preparation method thereof | |
| CN106265548A (en) | A kind of preparation method of carbamazepine dispersible tablet | |
| CN106860408B (en) | Glimepiride tablet | |
| CN113712930A (en) | Sitagliptin phosphate tablet and preparation method thereof | |
| CN105534980B (en) | The pharmaceutical composition and its preparation process of Repaglinide Metformin hydrochloride | |
| CN109700773B (en) | Ticagrelor preparation composition and preparation method thereof | |
| WO2019101150A1 (en) | Hs-25 tablet and preparation method therefor | |
| CN102370629B (en) | Entecavir liquid capsule and preparation method thereof | |
| CN104000821B (en) | Oral double-layer tablet containing telmisartan and amlodipine besylate and preparation method thereof | |
| CN104352465A (en) | Prucalopride succinate pharmaceutical composition free of silicon dioxide and preparation method of prucalopride succinate pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: Haikou standard structure building 570, No. 3113, Haikou Industrial Park, Haikou, Haixin high tech Zone, Hainan Province Patentee after: Huayi Taikang Pharmaceutical Co.,Ltd. Address before: 571100 Haikou City, Hainan Province, 273 Nanhai Avenue Haikou High-tech Zone D light steel structure standard industrial plant west side Patentee before: HAINAN VISUM PHARMACEUTICAL Co.,Ltd. |